SCHEMBL11511876

SCHEMBL11511876

O=C(O)[C@H]1NCCN[C@@H]1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A2 P43004 2/20 0.59
MEN1 O00255 1/20 0.54
BLM P54132 1/20 0.54
KMT2A Q03164 1/20 0.54
PKM P14618 1/20 0.44
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ARG1 P05089 5/20 0.42
ARG2 P78540 1/20 0.42
TSHR P16473 2/20 0.39
GABRP O00591 1/20 0.39
GABRD O14764 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2806367 1.00 SLC1A2 (0.59) SLC1A2MEN1BLMKMT2APKM
SCHEMBL11511873 1.00 SLC1A2 (0.59) SLC1A2MEN1BLMKMT2APKM
SCHEMBL2806369 1.00 SLC1A2 (0.59) SLC1A2MEN1BLMKMT2APKM
SCHEMBL7322888 0.81 SLC1A2 (0.48) SLC1A2MEN1BLMKMT2APKM
SCHEMBL28948796 0.81 SLC1A2 (0.43) SLC1A2MEN1BLMKMT2APKM
SCHEMBL11107498 0.80 SLC1A2 (0.46) SLC1A2MEN1BLMKMT2APKM
SCHEMBL9511237 0.76 SLC1A2 (0.39) SLC1A2MEN1BLMKMT2AALDH1A1
SCHEMBL4339884 0.75 SLC1A2 (0.43) SLC1A2MEN1BLMKMT2APKM
SCHEMBL4332743 0.75 SLC1A2 (0.43) SLC1A2MEN1BLMKMT2AALDH1A1
SCHEMBL1364961 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240166649-A1 DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHANGHAI VISONPHARMA CO., LTD. (CN) 2024-05-23 US disclosed
EP-4293022-A1 DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Visonpharma Co., Ltd. (CN) 2023-12-20 EP disclosed
WO-2022171072-A1 DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海维申医药有限公司 2022-08-18 WO disclosed
US-4142061-A FOR STABILIZING COBALT CABONYL CATALYST CHEVRON RESEARCH COMPANY (US) 1979-02-27 US disclosed
US-4096191-A Hydroformylation of olefins using azoxy-dentated ligands CHEVRON RESEARCH COMPANY (US) 1978-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166649-A1 DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF DPYD, GOT1, WEE1 SLC1A2 2851/4885MEN1 2128/4885BLM 1261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.